Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
Patents for C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
11/2003
11/27/2003WO2003097622A2 Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
11/27/2003WO2003097617A1 Cysteine protease inhibitors
11/27/2003WO2003097606A1 New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
11/27/2003WO2003097605A1 Pesticidal pyridinecarboxamide derivatives
11/27/2003WO2003097604A1 Pyridine carboxamide derivatives and their use as pesticides
11/27/2003WO2003097603A1 Process for the preparation of highly pure torsemide
11/27/2003WO2003097602A1 Cyanoguanidine produgs
11/27/2003WO2003097601A1 Cyanoguanidine prodrugs
11/27/2003WO2003097587A2 Gelling agents
11/27/2003WO2003097586A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003WO2003097582A2 Synthesis of benzonitriles and benzimidates
11/27/2003WO2003097576A2 Diamino-functional chalcones
11/27/2003WO2003097575A2 Amino-functional chalcones
11/27/2003WO2003097574A2 Aminoalkoxy-functional chalcones
11/27/2003WO2003097568A1 Process for producing 4-phenyl-4-oxo-2-butenoic ester derivative
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003009850A1 Substituted piperazines as modulators of the melanocortin receptor
11/27/2003WO2003006425A3 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
11/27/2003WO2002100813A3 Modulators of peroxisome proliferator activated receptors
11/27/2003WO2002074735A3 Biurethane derivatives
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003US20030220521 A conjugate compound comprising an antagonist of adrenergic neurotransmitter, and second residue is capable of being cleaved by a kidney enzyme; sodium channel modulators, hypotensive agents
11/27/2003US20030220504 Forming a phenyl-thiazoles chemical intermediates for making antioxidants, ferrielectric liquid crystal dopant, picornaviral viricides, antiinflammatory agents, anti-asthma agents, and fibringoen antagonists
11/27/2003US20030220499 Novel spiro compounds
11/27/2003US20030220498 Use of toxicologically benign iron salts or iron complexes as the catalysts, and commercially attractive aryl chlorides as well as various aryl sulfonates and aryl phosphonates can be used as starting materials
11/27/2003US20030220399 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220366 Nicotinamide derivatives useful as PDE4 inhibitors
11/27/2003US20030220352 Benzylated PDE4 inhibitors
11/27/2003US20030220350 For example, 3-(4-((N-(5-chlorobenzo(B)thiophen-3-carbonyl)-N-(2,2-diphenyl ethyl)amino)methyl)benzoylamino)propionic acid; for treatment or prevention of glucagon-mediated diseases such as diabetes
11/27/2003US20030220326 Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
11/27/2003US20030220324 Substituted piperazines and methods of use
11/27/2003US20030220323 Such as (2-(4-(2-(1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy)-1-phenyl-ethyl) -piperazin-1-yl)-ethoxy)-acetic acid; for prevention and/or treatment of conditions associated with pathogical levels of substance P
11/27/2003US20030220298 Combrestatin a-1 phosphate and combrestatin b-1 phosphate prodrugs
11/27/2003US20030220196 Phenyl-substituted-2enamino-keto nitriles
11/27/2003US20030219832 Administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors
11/27/2003CA2486092A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003CA2484671A1 Cyanoguanidine prodrugs
11/27/2003CA2484011A1 Cysteine protease inhibitors
11/27/2003CA2483619A1 Novel compounds and their use
11/26/2003EP1364974A2 Substituted pyridyl amine ligands, complexes, catalysts and processes for polymerizing and polymers
11/26/2003EP1364943A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors
11/26/2003EP1364941A1 Gelling agents
11/26/2003EP1364647A1 Hypoglycemic agent
11/26/2003EP1363886A1 Process and catalyst for the preparation of acetylpyridines
11/26/2003EP1363885A1 Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
11/26/2003EP1363884A2 Pyridine-substituted benzanilides as potassium ion channel openers
11/26/2003EP1363875A2 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity
11/26/2003EP1363874A2 Tryptase inhibitors
11/26/2003EP1363873A2 Peptide deformylase inhibitors
11/26/2003EP1363702A1 Methods of inhibiting kinases
11/26/2003EP1363644A2 Modulation of gsk-3beta activity and its different uses
11/26/2003EP1144380A4 A meta-nitro phenol derivative and a process for producing it
11/26/2003EP1000046B1 Piperazine derivatives active on the lower urinary tract
11/26/2003EP0757038B1 Benzamide compound and medicinal use thereof
11/26/2003CN1458929A Chemokine receptor binding heterocyclic compounds
11/26/2003CN1458926A Nitric oxide donors based on metallic centres
11/26/2003CN1458148A Process for preparing w-mercapto-alkyl-pyridine
11/26/2003CN1458143A Process for preparing N-aroyl-L-glutaminic acid
11/26/2003CN1128619C Utilization of powder prepns. contg. hydroxypyridones treating leg ulcer and decubitus ulcers
11/25/2003US6653654 Light emitting diodes having electrodes, charge tranfer compounds, emitter layers comprising mixtures of beryllium bis(2-(2'-hydroxyphenyl)pyridine) and platinum complexes as dopes; brightness; heat resistance
11/25/2003US6653331 Targeted drug delivery using sulfonamide derivatives
11/25/2003US6653326 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
11/25/2003US6653323 Aryl aniline β2 adrenergic receptor agonists
11/25/2003US6653321 Stimulating kinase activity of insulin receptor; type II diabetes; hyperglycemia
11/25/2003US6653311 Minimal or no effect on cycloxygenase-1 and -2 activity
11/25/2003US6653310 For therapy of disease states mediated by the chemokine, Interleukin-8 (IL-8)
11/25/2003US6653309 Binding ligands
11/25/2003US6653258 Pyridinyl-substituted- methyl 3-methoxy-2-phenylacrylate derivatives; agricultural miticides and nematocides
11/25/2003US6652905 Piezoelectric element and process for production thereof
11/20/2003WO2003095701A1 Volatile copper(ii) complexes for deposition of copper films by atomic layer deposition
11/20/2003WO2003095446A1 Process for producing 1-(4-pyridyl)-4-piperidone
11/20/2003WO2003095438A1 Substituted phenylacetamides and their use as glucokinase activators
11/20/2003WO2003095421A1 Amino acid analogues
11/20/2003WO2003094934A1 Medicine for prevention of and treatment for amyloidosis
11/20/2003WO2003094918A1 Substituted piperazine as melanocortin receptors ligands
11/20/2003WO2003094845A2 Pyridine-based thyroid receptor ligands
11/20/2003WO2003087062A3 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
11/20/2003WO2003066023A9 A stable pharmaceutical formulation comprising torsemide modification ii
11/20/2003WO2003051276A3 Therapeutic heterocycles
11/20/2003WO2003050087A3 Novel herbicides
11/20/2003WO2003008559A3 Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
11/20/2003WO2002032869A8 Substituted heterocyclic compounds for treating multidrug resistance
11/20/2003WO2002028836A9 Novel crystalline forms of a factor xa inhibitor
11/20/2003US20030216603 Fluorinated quaternary ammonium salt
11/20/2003US20030216586 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them
11/20/2003US20030216578 Reacting pyridine with hydrogen sulfide in presence of tertiary amine
11/20/2003US20030216577 Catalytic ozonolysis using transition metal catalys
11/20/2003US20030216569 Viricides; Aids therapy
11/20/2003US20030216450 Inhibitors of dipeptidyl peptidase IV
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216445 Osteoporosis; immunosuppressants; wound healing agent
11/20/2003US20030216444 Controlling plant disease
11/20/2003US20030216442 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus
11/20/2003US20030216409 Heteroaryl alkyl piperazine derivatives
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216403 An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma
11/20/2003US20030216396 An urea compounds containing a pyridine, quinoline, or isoquinoline functionality, which are useful in the treatment of cancer, inflammation, osteoporosis and angiogenesis
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
1 ... 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 ... 633